The present disclosure relates to preparations of RNI, such as dual fiber RNI preparations of RNI, which can inhibit gene expression of 17b hydroxycholesterol dehydrogenase type 13 (hsd17 B13 or 17b-hsd13). In addition, the drug synthesis and use methods between Arni company and hsd17 B13 company were also published. Agents of Arni and hsd17b13, if disclosed in this report, can be combined into a target coalition to facilitate transfer to cells, including hepatocytes.la presente divulgación se refiere a agentes de arni, por ejemplo, agentes de arni de doble hebra, capaces de inhibir la expresión génica de 17ß-hidroxiesteroide deshidrogenasa tipo 13 (hsd17b13 o 17ß-hsd13). asimismo, se dan a conocer composiciones farmacéuticas que comprenden agentes de arni contra hsd17b13 y métodos para la utilización de las mismas. los agentes de arni contra hsd17b13 conforme a lo divulgado en la presente memoria pueden estar conjugados a ligandos dirigidos a la diana para facilitar el transporte hacia las células, incluidos los hepatocitos.
